- Home
- FSEA vs ACRV Comparison
FSEA vs ACRV Comparison
Compare FSEA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- ACRV
- Stock Information
- Founded
- FSEA 1890
- ACRV 2018
- Country
- FSEA United States
- ACRV United States
- Employees
- FSEA N/A
- ACRV N/A
- Industry
- FSEA Savings Institutions
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- FSEA Finance
- ACRV Health Care
- Exchange
- FSEA Nasdaq
- ACRV Nasdaq
- Market Cap
- FSEA 51.2M
- ACRV 42.5M
- IPO Year
- FSEA N/A
- ACRV 2022
- Fundamental
- Price
- FSEA N/A
- ACRV $1.81
- Analyst Decision
- FSEA
- ACRV Strong Buy
- Analyst Count
- FSEA 0
- ACRV 6
- Target Price
- FSEA N/A
- ACRV $21.80
- AVG Volume (30 Days)
- FSEA 14.2K
- ACRV 412.6K
- Earning Date
- FSEA 05-09-2025
- ACRV 05-13-2025
- Dividend Yield
- FSEA N/A
- ACRV N/A
- EPS Growth
- FSEA N/A
- ACRV N/A
- EPS
- FSEA N/A
- ACRV N/A
- Revenue
- FSEA $15,874,000.00
- ACRV N/A
- Revenue This Year
- FSEA N/A
- ACRV N/A
- Revenue Next Year
- FSEA N/A
- ACRV N/A
- P/E Ratio
- FSEA N/A
- ACRV N/A
- Revenue Growth
- FSEA 70.41
- ACRV N/A
- 52 Week Low
- FSEA $8.30
- ACRV $1.30
- 52 Week High
- FSEA $11.69
- ACRV $11.51
- Technical
- Relative Strength Index (RSI)
- FSEA 44.41
- ACRV 34.69
- Support Level
- FSEA $10.81
- ACRV $1.30
- Resistance Level
- FSEA $11.18
- ACRV $2.19
- Average True Range (ATR)
- FSEA 0.37
- ACRV 0.32
- MACD
- FSEA -0.06
- ACRV 0.10
- Stochastic Oscillator
- FSEA 41.43
- ACRV 51.00
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities and bank-owned life insurance.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.